Lanzi Anastasia, Sinicrope F A, Benson A B, Galon Jérôme
INSERM, Laboratory of Integrative Cancer Immunology, Cordeliers Research Center, Paris, France.
Equipe Labellisée Ligue Contre le Cancer, Paris, France.
Oncoimmunology. 2020 Jul 20;9(1):1796003. doi: 10.1080/2162402X.2020.1796003.
The consensus Immunoscore is a routine assay quantifying the adaptive immune response within the tumor microenvironment. It has a prognostic value that has been confirmed in a phase 3 clinical trial (NCCTG N0147) in stage III colon cancers. Moreover, results from another phase 3 randomized trial revealed the predictive value of Immunoscore for response to adjuvant chemotherapy duration. These results highlight the clinical utility of Immunoscore. In its latest edition, the World Health Organization classification of Digestive System Tumors introduced for the first time the immune response as an essential and desirable diagnostic criterion for colorectal cancer. Within the tumor microenvironment, the immune response provides an important estimate of the risk of recurrence and death in colon cancer. The international validation of the prognostic value of the consensus Immunoscore together with its prognostic value in the N0147 trial and its predictive utility for response to chemotherapy in stage III patients provide valuable information for patient management.
共识免疫评分是一种常规检测方法，用于量化肿瘤微环境中的适应性免疫反应。其预后价值已在一项针对III期结肠癌的3期临床试验（NCCTG N0147）中得到证实。此外，另一项3期随机试验的结果揭示了免疫评分对辅助化疗持续时间反应的预测价值。这些结果凸显了免疫评分的临床实用性。在其最新版本中，世界卫生组织消化系统肿瘤分类首次将免疫反应作为结直肠癌的一项重要且理想的诊断标准。在肿瘤微环境中，免疫反应为结肠癌的复发风险和死亡风险提供了重要评估。共识免疫评分预后价值的国际验证、其在N0147试验中的预后价值以及对III期患者化疗反应的预测效用，为患者管理提供了有价值的信息。
